{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:20:09Z","timestamp":1791908409763,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012834","name":"Gifu University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012834","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Diffuse large B-cell lymphoma (DLBCL) predominantly affects older adults, with an increasing proportion of patients aged\u2009\u2265\u200980 years. Although the POLARIX trial demonstrated improved progression-free survival with polatuzumab vedotin (Pola) combined with R-CHP (Pola-R-CHP), its applicability to very elderly patients remains unclear. A multicenter, retrospective, cohort study was conducted at seven hospitals in Japan, enrolling 172 previously untreated DLBCL patients who initiated Pola-R-CHP between August 1, 2022 and May 1, 2024. Patients were stratified by age (&lt;\u200980 vs. \u226580 years). Initial dose intensity (IDI), average relative dose intensity (ARDI), treatment efficacy, and safety outcomes were evaluated. In patients aged\u2009\u2265\u200980 years (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200944), the overall response rate (ORR) was 89.5%, comparable to the 97.3% in patients aged\u2009&lt;\u200980 years. However, treatment-related mortality (TRM) was higher in the older group (11.4% vs. 2.3%). In this cohort, median IDI and ARDI for doxorubicin and cyclophosphamide were markedly lower, whereas Pola dosing was relatively preserved. Higher Pola IDI was associated with an increased incidence of severe adverse events (sAEs), and a lower Geriatric Nutritional Risk Index (GNRI) was independently correlated with both reduced ORR and increased sAEs. Pola-R-CHP demonstrates promising efficacy in DLBCL patients aged\u2009\u2265\u200980 years. However, the increased TRM highlights the importance of cautious toxicity management. Individualized dose modifications, particularly for cytotoxic agents, and comprehensive nutritional assessments may improve treatment tolerability and outcomes in this vulnerable population.\n                  <\/jats:p>","DOI":"10.1007\/s00277-025-06619-0","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T02:32:39Z","timestamp":1760063559000},"page":"5191-5200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: a real-world study"],"prefix":"10.1007","volume":"104","author":[{"given":"Toshiki","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1682-7777","authenticated-orcid":false,"given":"Nobuhiko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideko","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senji","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Fukuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hayase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Suzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Kanemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Tsurumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"6619_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G (2021) Diffuse large B-cell lymphoma. N Engl J Med 384:842\u2013858. https:\/\/doi.org\/10.1056\/NEJMra2027612","journal-title":"N Engl J Med"},{"key":"6619_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.35772\/ghm.2019.01011","volume":"1","author":"H Nakatani","year":"2019","unstructured":"Nakatani H (2019) Population aging in Japan: policy transformation, sustainable development goals, universal health coverage, and social determinates of health. Glob Health Med 1:3\u201310. https:\/\/doi.org\/10.35772\/ghm.2019.01011","journal-title":"Glob Health Med"},{"key":"6619_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/onco.13610","volume":"26","author":"M Di","year":"2021","unstructured":"Di M, Huntington SF, Olszewski AJ (2021) Challenges and opportunities in the management of diffuse large B-cell lymphoma in older patients. Oncologist 26:120\u2013132. https:\/\/doi.org\/10.1002\/onco.13610","journal-title":"Oncologist"},{"key":"6619_CR4","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1182\/blood.2020008239","volume":"141","author":"PJ Lugtenburg","year":"2023","unstructured":"Lugtenburg PJ, Mutsaers PGNJ (2023) How i treat older patients with DLBCL in the frontline setting. Blood 141:2566\u20132575. https:\/\/doi.org\/10.1182\/blood.2020008239","journal-title":"Blood"},{"key":"6619_CR5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH et al (2022) Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 386:351\u2013363. https:\/\/doi.org\/10.1056\/NEJMoa2115304","journal-title":"N Engl J Med"},{"key":"6619_CR6","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3960\/jslrt.23043","volume":"63","author":"Y Sekiguchi","year":"2023","unstructured":"Sekiguchi Y, Tsutsumi H, Gomyo A et al (2023) Use of R-mini-CHP in combination with polatuzumab Vedotin (pola-R-mini-CHP) as the primary treatment in \u2265 80-year-old cases with diffuse large B-cell lymphoma. J Clin Exp Hematop 63:262\u2013265. https:\/\/doi.org\/10.3960\/jslrt.23043","journal-title":"J Clin Exp Hematop"},{"key":"6619_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s44313-025-00059-5","volume":"60","author":"S Sato","year":"2025","unstructured":"Sato S, Tsunoda S, Kamata W et al (2025) Real-world effectiveness and safety of rituximab and reduced-dose CHP with polatuzumab Vedotin (pola-R-CHP) in patients aged\u2009>\u200980 years with diffuse large B-cell lymphoma: a retrospective analysis. Blood Res 60:10. https:\/\/doi.org\/10.1007\/s44313-025-00059-5","journal-title":"Blood Res"},{"key":"6619_CR8","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med 329:987\u2013994. https:\/\/doi.org\/10.1056\/NEJM199309303291402","journal-title":"N Engl J Med"},{"issue":"4","key":"6619_CR9","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/ajcn\/82.4.777","volume":"82","author":"O Bouillanne","year":"2005","unstructured":"Bouillanne O, Morineau G, Dupont C et al (2005) Geriatric nutritional risk index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr 82(4):777\u2013783. https:\/\/doi.org\/10.1093\/ajcn\/82.4.777","journal-title":"Am J Clin Nutr"},{"key":"6619_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275\u2013282. https:\/\/doi.org\/10.1182\/blood-2003-05-1545","journal-title":"Blood"},{"key":"6619_CR11","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"6619_CR12","unstructured":"National Cancer Institute (2007) Common Terminology Criteria for Adverse Events (CTCAE) v5.0"},{"key":"6619_CR13","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/bjh.18348","volume":"198","author":"M Picardi","year":"2022","unstructured":"Picardi M, Giordano C, Pugliese N et al (2022) Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical hodgkin lymphoma: preliminary results of a single-centre phase II study. Br J Haematol 198:847\u2013860. https:\/\/doi.org\/10.1111\/bjh.18348","journal-title":"Br J Haematol"},{"key":"6619_CR14","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/ehf2.13879","volume":"9","author":"A Cuomo","year":"2022","unstructured":"Cuomo A, Mercurio V, Varricchi G et al (2022) Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients. ESC Heart Fail 9:1666\u20131676. https:\/\/doi.org\/10.1002\/ehf2.13879","journal-title":"ESC Heart Fail"},{"issue":"9","key":"6619_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14093257","volume":"14","author":"E Topa","year":"2025","unstructured":"Topa E, De Rosa E, Cuomo A et al (2025) Cardio-oncology challenges in elderly patients. J Clin Med 14(9):3257. https:\/\/doi.org\/10.3390\/jcm14093257","journal-title":"J Clin Med"},{"key":"6619_CR16","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","volume":"12","author":"F Peyrade","year":"2011","unstructured":"Peyrade F, Jardin F, Thieblemont C et al (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 12:460\u2013468. https:\/\/doi.org\/10.1016\/S1470-2045(11)70069-9","journal-title":"Lancet Oncol"},{"issue":"S3","key":"6619_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/01.hs9.0000967820.91359.ec","volume":"7","author":"M Jerkeman","year":"2023","unstructured":"Jerkeman M, Lepp\u00e4 S, Hamfjord J et al (2023) S227: initial safety data from the phase 3 POLAR BEAR trial in elderly or frail patients with diffuse large cell lymphoma, comparing R-POLA-MINI-CHP and R-MINI-CHOP. HemaSphere 7(S3):e91359ec. https:\/\/doi.org\/10.1097\/01.hs9.0000967820.91359.ec","journal-title":"HemaSphere"},{"key":"6619_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJM199807023390104","volume":"339","author":"TP Miller","year":"1998","unstructured":"Miller TP, Dahlberg S, Cassady JR et al (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin\u2019s lymphoma. N Engl J Med 339:21\u201326. https:\/\/doi.org\/10.1056\/NEJM199807023390104","journal-title":"N Engl J Med"},{"key":"6619_CR19","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1200\/JCO.2007.13.6929","volume":"26","author":"DO Persky","year":"2008","unstructured":"Persky DO, Unger JM, Spier CM et al (2008) Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: southwest oncology group study 0014. J Clin Oncol 26:2258\u20132263. https:\/\/doi.org\/10.1200\/JCO.2007.13.6929","journal-title":"J Clin Oncol"},{"key":"6619_CR20","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1080\/13696998.2023.2254162","volume":"26","author":"T Mizuoka","year":"2023","unstructured":"Mizuoka T, Sakamaki H, Fuji S et al (2023) Cost-effectiveness of combination therapy of polatuzumab Vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan. J Med Econ 26:1122\u20131133. https:\/\/doi.org\/10.1080\/13696998.2023.2254162","journal-title":"J Med Econ"},{"key":"6619_CR21","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1080\/13696998.2023.2254640","volume":"26","author":"M Matasar","year":"2023","unstructured":"Matasar M, Masaquel A, Ho S R, et al (2023) US cost-effectiveness analysis of polatuzumab Vedotin in previously untreated diffuse large B-cell lymphoma. J Med Econ 26:1134\u20131144. https:\/\/doi.org\/10.1080\/13696998.2023.2254640","journal-title":"J Med Econ"},{"key":"6619_CR22","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.3324\/haematol.2019.234435","volume":"105","author":"S Lee","year":"2020","unstructured":"Lee S, Fujita K, Negoro E et al (2020) Impact of relative dose intensity of standard regimens on survival in elderly patients aged 80 years and older with diffuse large B-cell lymphoma. Haematologica 105:e415\u2013e418. https:\/\/doi.org\/10.3324\/haematol.2019.234435","journal-title":"Haematologica"},{"key":"6619_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2217\/fon-2020-0675","volume":"17","author":"V Camus","year":"2021","unstructured":"Camus V, Tilly H (2021) Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed\/refractory diffuse large B-cell lymphoma. Future Oncol 17:127\u2013135. https:\/\/doi.org\/10.2217\/fon-2020-0675","journal-title":"Future Oncol"},{"key":"6619_CR24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.21037\/amj-23-188","volume":"9","author":"R Hsu","year":"2024","unstructured":"Hsu R, Nieva JJ (2024) A narrative review of the efficacy and safety FDA-approved antibody-drug conjugates in older patients. AME Med J 9:24\u201324. https:\/\/doi.org\/10.21037\/amj-23-188","journal-title":"AME Med J"},{"key":"6619_CR25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/bjh.16743","volume":"192","author":"S Lee","year":"2021","unstructured":"Lee S, Fujita K, Morishita T et al (2021) Prognostic utility of a geriatric nutritional risk index in combination with a comorbidity index in elderly patients with diffuse large B cell lymphoma. Br J Haematol 192:100\u2013109. https:\/\/doi.org\/10.1111\/bjh.16743","journal-title":"Br J Haematol"},{"key":"6619_CR26","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jgo.2022.02.005","volume":"13","author":"OS Akhtar","year":"2022","unstructured":"Akhtar OS, Huang L-W, Tsang M, et al (2022) Geriatric assessment in older adults with non-Hodgkin lymphoma: A Young International Society of Geriatric Oncology (YSIOG) review paper. J Geriatr Oncol 13:572\u2013581.https:\/\/doi.org\/10.1016\/j.jgo.2022.02.005","journal-title":"J Geriatr Oncol"},{"key":"6619_CR27","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1038\/s41598-022-07164-w","volume":"12","author":"T Tanaka","year":"2022","unstructured":"Tanaka T, Sakai R, Tanaka T, Choi I et al (2022) Comprehensive geriatric assessment as a useful tool in predicting adverse events in elderly patients with diffuse large B-cell lymphoma. Sci Rep 12:3124. https:\/\/doi.org\/10.1038\/s41598-022-07164-w","journal-title":"Sci Rep"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06619-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06619-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06619-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T08:19:25Z","timestamp":1763194765000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06619-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":27,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6619"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06619-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7112709\/v1","asserted-by":"object"}]},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"13 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Gifu University Graduate School of Medicine (approval number: 2022\u2009\u2212\u2009221).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Due to the retrospective nature of the study and the use of anonymized data, the requirement for informed consent was waived by the ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Nobuhiko Nakamura received honoraria from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., AbbVie GK, Janssen Pharmaceutical K.K., Sanofi, Novartis, MSD K.K., Sumitomo Pharma Co., Ltd., Nippon Kayaku Co., Ltd., Nippon Shinyaku Co., Ltd., Meiji Seika Pharma Co., Ltd., and AstraZeneca K.K. The remaining authors have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}